Prolia's generic name is denosumab [1].
What is Prolia (denosumab) used for?
Denosumab is a medication used to treat several conditions related to bone health. It is prescribed to women who have gone through menopause and are at high risk of fractures due to osteoporosis. It also treats bone loss in men and women undergoing treatment for prostate or breast cancer, respectively, and helps increase bone mass in certain patients. Additionally, denosumab is used to treat giant cell tumor of bone in adults and adolescents where surgical resection is likely to cause severe morbidity [1].
How does denosumab work?
Denosumab is a human monoclonal antibody that works by inhibiting osteoclast formation, function, and survival. Osteoclasts are cells responsible for bone resorption, the breakdown of bone tissue. By reducing bone resorption, denosumab helps to increase bone mineral density and reduce the risk of fractures [1].
When does the patent for denosumab expire?
Patent information for drugs can be complex and involve multiple patents covering different aspects of the drug. Information from DrugPatentWatch.com indicates that various patents related to denosumab have expiration dates in the coming years, with some potentially expiring in the mid-to-late 2020s and early 2030s [2]. Specific patent expiry dates can vary depending on the country and the particular patent.
Are there any generic versions of denosumab available?
As of now, there are no FDA-approved generic versions of denosumab available in the United States. The availability of generic alternatives typically follows the expiration of relevant patents and regulatory approval processes for biosimilars [3].
What are the common side effects of denosumab?
Common side effects of denosumab can include pain in the extremities, muscle pain, and eczema [1]. More serious potential side effects, though less common, involve a low level of calcium in the blood (hypocalcemia), severe infections, and osteonecrosis of the jaw, a condition where bone tissue dies [1].
What is the difference between Prolia and other osteoporosis treatments?
Prolia (denosumab) is a biologic drug that works differently than many other osteoporosis medications. Bisphosphonates, a common class of osteoporosis drugs, are taken orally or intravenously and work by slowing down bone loss. Denosumab, administered as an injection, targets a specific protein (RANKL) involved in bone breakdown, offering a different mechanism of action. The choice of treatment often depends on individual patient factors, risk factors for fracture, and tolerance for side effects [1].